Try our new research platform with insights from 80,000+ expert users

Jedox vs Prodacapo [EOL] comparison

 

Comparison Buyer's Guide

Executive Summary

Review summaries and opinions

We asked business professionals to review the solutions they use. Here are some excerpts of what they said:
 

Categories and Ranking

Jedox
Average Rating
8.0
Reviews Sentiment
6.7
Number of Reviews
13
Ranking in other categories
Business Performance Management (11th)
Prodacapo [EOL]
Average Rating
0.0
Number of Reviews
0
Ranking in other categories
No ranking in other categories
 

Featured Reviews

Riyaz Halani - PeerSpot reviewer
Powerful BI tool for analyzing financial performance and stable performance
I would rate the scalability of Jedox a seven out of ten. There is room for improvement in the scalability. It is a very massive tool. It's not easy to just build everything yourself. So that's where the main improvements lie—making it easy for people to not depend on just technical finance teams. There are almost 50 to 60 users using Jedox in our organization.
Use Prodacapo [EOL]?
Share your opinion
report
Use our free recommendation engine to learn which Business Performance Management solutions are best for your needs.
867,676 professionals have used our research since 2012.
 

Top Industries

By visitors reading reviews
Retailer
13%
Computer Software Company
13%
Comms Service Provider
10%
Manufacturing Company
8%
No data available
 

Company Size

By reviewers
Large Enterprise
Midsize Enterprise
Small Business
By reviewers
Company SizeCount
Small Business6
Midsize Enterprise3
Large Enterprise4
No data available
 

Comparisons

 

Also Known As

Jedox EPM
No data available
 

Overview

 

Sample Customers

BP, Fiat, Carrefour, Continental, Allianz, Bacardi, McDonald’s, Netafim, Swiss Post, Telstra, Suzuki, Vodafone, University of Western Australia, Unilever
Pipeline Group
Find out what your peers are saying about Oracle, Anaplan, IBM and others in Business Performance Management. Updated: September 2025.
867,676 professionals have used our research since 2012.